Curt P. Richter award winner
Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders

https://doi.org/10.1016/0306-4530(95)00011-9Get rights and content

Abstract

Corticotropin-releasing factor (CRF) plays a major role in coordinating the endocrine, autonomic, behavioral and immune responses to stress through actions in the brain and the periphery. CRF receptors identified in brain, pituitary and spleen have comparable kinetic and pharmacological characteristics, guanine nucleotide sensitivity and adenylate cyclase-stimulating activity. Differences were observed in the molecular mass of the CRF receptor complex between the brain (58,000 Da) and the pituitary and spleen (75,000 Da), which appeared to be due to differential glycosylation of the receptor proteins. The recently cloned CRF receptor in the pituitary and the brain (designated as CRF,) encodes a 415 amino acid protein comprising seven putative membrane-spanning domains and is structurally related to the calcitonin/vasoactive intestinal peptide/growth hormone-releasing hormone subfamily of G-protein-coupled receptors. A second member of the CRF receptor family encoding a 411 amino acid rat brain protein with ≈70% homology to CRF, has recently been identified designated as CRF2); there exists an additional splice variant of the CRF2 receptor with a different N-terminal domain encoding a protein of 431 amino acids. In autoradiographic studies, CRF receptors were localized in highest densities in the anterior and intermediate lobes of the pituitary gland, olfactory bulb, cerebral cortex, amygdala, cerebellum and the macrophage-enriched zones and red pulp regions of the spleen. CRF can modulate the number of CRF receptors in a reciprocal manner. For example, stress and adrenalectomy increase hypothalamic CRF secretion which, in turn, down-regulates CRF receptors in the anterior pituitary. CRF receptors in the brain and pituitary are also altered as a consequence of the development and aging processes. In addition to a physiological role for CRF in integrating the responses of the brain, endocrine and immune systems to physiological, psychological and immunological stimuli, recent clinical data implicate CRF in the etiology and pathophysiology of various endocrine, psychiatric, neurologic and inflammatory illnesses. Hypersecretion of CRF in the brain may contribute to the symptomatology seen in neuropsychiatric disorders, such as depression, anxiety-related disorders and anorexia nervosa. Furthermore, overproduction of CRF at peripheral inflammatory sites, such as synovial joints may contribute to autoimmune diseases such as rheumatoid arthritis. In contrast, deficits in brain CRF are apparent in neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, as they relate to dysfunction of CRF neurons in the brain areas affected in the particular disorder. Strategies directed at developing CRF-related agents may hold promise for novel therapies for the treatment of these various disorders.

References (144)

  • E.B. De Souza et al.

    Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease

    Brain Res

    (1987)
  • A.J. Dunn et al.

    Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety of stress responses?

    Brain Res Rev

    (1990)
  • L.B. Eberly et al.

    Iontophoretic mapping of corticotropin-releasing factor (CRF) sensitive neurons in the rat forebrain

    Peptides

    (1983)
  • D.E. Grigoriadis et al.

    The brain corticotropin-releasing factor (CRF) receptor is of lower apparent molecular weight than the CRF receptor in anterior pituitary: evidence from chemical cross-linking studies

    J Biol Chem

    (1988)
  • D.E. Grigoriadis et al.

    Corticotropin-releasing factor receptors in intermediate lobe of the pituitary: biochemical characterization and autoradiographic localization

    Peptides

    (1989)
  • D.E. Grigoriadis et al.

    Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in Alzheimer's disease: evidence from chemical cross-linking studies

    Neuropharmacology

    (1989)
  • J.A. Heroux et al.

    Age-related decreases in corticotropin-releasing factor (CRF) receptors in rat brain and anterior pituitary gland

    Brain Res

    (1991)
  • F. Holsboer et al.

    ACTH and multisteroid responses to corticotropin-releasing factor in depressive illness: relationship to multisteroid responses after ACTH stimulation and dexamethasone suppression

    Psychoneuroendocrinology

    (1984)
  • G. Ixart et al.

    Evidence for basal and stress-induced release of corticotropin releasing factor in the push-pull cannulated median eminence of conscious free-moving rats

    Neurosci Lett

    (1987)
  • J. Korf et al.

    Increased turnover of norepinephrine in red cerebral cortex during stress: role of the locus coeruleus

    Neuropharmacology

    (1973)
  • I. Merchenthaler et al.

    Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat spinal cord

    Brain Res

    (1983)
  • H. Meunier et al.

    CRF stimulates alpha-MSH secretion and cyclic AMP accumulation in rat pars intermedia cells

    Life Sci

    (1982)
  • M.M. Mouradian et al.

    Spinal fluid CRF reduction in Alzheimer's disease

    Neuropeptides

    (1986)
  • E. Nishimura et al.

    Identification and characterization of a pituitary corticotropin-releasing factor binding protein by chemical cross-linking

    J Biol Chem

    (1987)
  • J.A. Olschowka et al.

    The distribution of corticotropinreleasing factor-like immunoreactive neurons in rat brain

    Peptides

    (1982)
  • N. Ono et al.

    Intrahypothalamic action of corticotropin-releasing factor (CRF) to inhibit growth hormone and LH release in the rat

    Life Sci

    (1984)
  • T.N. Pappas et al.

    Corticotropin-releasing factor inhibits gastric emptying in dogs: studies on its mechanism of action

    Peptides

    (1987)
  • G. Aguilera et al.

    Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells

    J Biol Chem

    (1983)
  • G. Aguilera et al.

    Corticotropin releasing factor receptors: characterization and actions in the anterior pituitary gland

    Adv Exp Med Biol

    (1988)
  • G. Aguilera et al.

    Corticotropin-releasing factor receptors: distribution in brain, pituitary and peripheral tissues

    Ann NY Acad Sci

    (1987)
  • M.J. Bannon et al.

    Pharmacology of mesocortical dopamine neurons

    Pharmacol Rev

    (1983)
  • A.I. Basbaum et al.

    The contribution of the nervous system to inflammation and inflammatory disease

    Can J Physiol Pharmacol

    (1990)
  • G. Battaglia et al.

    Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system

    Synapse

    (1987)
  • J.A. Bell et al.

    Functional corticotropin-releasing factor receptors in neonatal spinal cord

    Peptides

    (1989)
  • L.M. Bilezikjian et al.

    Glucocorticoids inhibit corticotropin-releasing factor-induced production of adenosine 3′,5′-monophosphate in cultured anterior pituitary cells

    Endocrinology

    (1983)
  • G. Bissette et al.

    Corticotropin-releasing factorlike immunoreactivity in senile dementia of the Alzheimer type

    JAMA

    (1985)
  • J.E. Blalock

    A molecular basis for bidirectional communication between the immune and neuroendocrine systems

    Physiol Rev

    (1989)
  • M.R. Brown et al.

    Regulation of the autonomic nervous system by corticotropin-releasing factor

  • M.R. Brown et al.

    Corticotropin-releasing factor: effects on the sympathetic nervous system and oxygen consumption

    Life Sci

    (1982)
  • M.R. Brown et al.

    Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism

    Endocrinology

    (1982)
  • A.E. Calogero et al.

    Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting a global defect in CRH secretion

    Neuroendocrinology

    (1992)
  • G. Cassens et al.

    Alternations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock

    Science

    (1980)
  • P.B. Chappell et al.

    Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress

    J Neurosci

    (1986)
  • F.M. Chen et al.

    CRF receptor mediated stimulation of adenylate cyclase activity in rat brain

    Brain Res

    (1986)
  • R. Chen et al.

    Expression cloning of a human corticotropinreleasing factor receptor

  • G.V. Childs et al.

    Cytochemical studies of corticotropin-releasing factor (CRF) receptors in anterior lobe corticotropes: binding, glucocorticoid regulation and endocytosis of [biotinyl-serl] CRF

    Endocrinology

    (1986)
  • I.C. Chinkanza et al.

    Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis

    Arthritis Rheum

    (1992)
  • J.T. Coyle et al.

    Alzheimer's disease: a disorder of cortical cholinergic innervation

    Science

    (1983)
  • L.J. Crofford et al.

    Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumathoid arthritis and osteoarthritis

    J Immunol

    (1993)
  • L.J. Crofford et al.

    Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis

    J Clin Invest

    (1992)
  • Cited by (349)

    • (3α,5α)3-hydroxypregnan-20-one (3α,5α-THP) regulation of hypothalamic and extrahypothalamic corticotropin releasing factor (CRF): Sexual dimorphism and brain region specificity in Sprague Dawley rats

      2021, Neuropharmacology
      Citation Excerpt :

      In fact, it has been observed that exacerbation of CRF signaling in extrahypothalamic regions, such as CeA, NAc and VTA, is related to positive reinforcement during the first stage of addiction, while increases in CRF levels in extended amygdala and dorsal striatum have been linked with negative emotional state and habitual drug-seeking in later stages of addiction (Zorrilla et al., 2014). Additionally, abnormal CRF physiology has been linked with neurogenerative disease, including Huntington's chorea (Heuser et al., 1991) and Alzheimer's disease (De Souza, 1995). Despite the negative correlation between aberrant CRF signaling and several neurologicaldiseases, there is evidence that CRF can also have a neuroprotective role.

    • Alcohol: Neurobiology of Addiction

      2021, Alcohol: Neurobiology of Addiction
    View all citing articles on Scopus
    View full text